10-KPeriod: FY2002

JOHNSON & JOHNSON Annual Report, Year Ended Dec 29, 2002

Filed March 18, 2003For Securities:JNJ

Summary

Johnson & Johnson's 2002 Form 10-K paints a picture of a diversified healthcare giant operating across three key segments: Consumer, Pharmaceutical, and Medical Devices & Diagnostics. The company's robust market position is underscored by its significant market capitalization, exceeding $156 billion in early 2003, indicating strong investor confidence. While the filing itself doesn't provide detailed financial performance for 2002, it outlines the organizational structure and regulatory environment JNJ operates within, highlighting its compliance with filing requirements and its status as an accelerated filer. Investors should note the comprehensive nature of JNJ's business, with operations spanning global markets and a focus on research and development to maintain its competitive edge. The company's reliance on patents and trademarks emphasizes the importance of innovation and intellectual property protection. The filing also acknowledges the highly regulated nature of the pharmaceutical and medical device industries, suggesting potential impacts from regulatory changes and legal proceedings, which are detailed further in the report.

Key Highlights

  • 1Johnson & Johnson is a diversified healthcare company with three primary business segments: Consumer, Pharmaceutical, and Medical Devices & Diagnostics.
  • 2The company held a significant market capitalization of approximately $156 billion as of the last business day of its second fiscal quarter, reflecting strong investor confidence.
  • 3JNJ is classified as an accelerated filer, indicating its substantial size and compliance with SEC reporting requirements.
  • 4The company's business is heavily reliant on patents and trademarks, underscoring the importance of innovation and intellectual property.
  • 5Operations are global, with the company participating in various geographic markets.
  • 6The filing acknowledges the importance of research and development in maintaining competitiveness.
  • 7The highly regulated nature of the pharmaceutical and medical device industries is a key operating factor.

Frequently Asked Questions

Johnson & Johnson operates through three main business segments: Consumer, Pharmaceutical, and Medical Devices & Diagnostics.

As of the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the voting and non-voting common stock held by non-affiliates was approximately $156 billion.

Yes, Johnson & Johnson is classified as an accelerated filer, which is a designation for larger public companies that meet certain reporting requirements.

Crucial factors for Johnson & Johnson's competitive position include its strong reliance on patents and trademarks, its ongoing investment in research and development, and its ability to navigate the highly regulated healthcare industry.